Preparation and evaluation of paclitaxel-containing liposomes - PubMed (original) (raw)
Affiliations
- PMID: 17341033
Preparation and evaluation of paclitaxel-containing liposomes
C Holvoet et al. Pharmazie. 2007 Feb.
Abstract
Paclitaxel, an antitumoral drug, is poorly soluble in aqueous media. Therefore, in a commercialised formulation (Taxol), paclitaxel (30 mg active compound) is dissolved in polyethoxylated castor oil (Cremophor EL) and ethanol. After dilution of Taxol in aqueous media paclitaxel tends to precipitate. Several side effects, attributed to the surfactant Cremophor EL, occur, e.g. bronchospasm, hypotension, neuro- and nephrotoxicity, and anaphylactic reactions. To eliminate these side effects, the solubility of paclitaxel was enhanced using liposomes instead of Cremophor EL. The amount of entrapped paclitaxel in crystal-free liposomes was 0.5 mg/ml liposome suspension, i.e. almost 85 times the native solubility. Thus, 30 mg paclitaxel had to be dissolved in 60 ml liposome suspension, of either multi-lamellar vesicles (MLV's) or of small unilamellar vesicles (SUV's) with 5% sucrose as cryoprotector. No precipitation was observed after dilution of the MLV-formulation with (physiological) water or with 5% aqueous dextrose solution, which proves their suitability for administration with perfusions. The chemical stability of paclitaxel in the prepared MLV's stored at 4 degrees C was demonstrated during a period of 5 months. The chemical degradation to conjugated dienes and hydroperoxides, two oxidative degradation products of EPC, was negligible (less than 1%).
Similar articles
- Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
Nornoo AO, Osborne DW, Chow DS. Nornoo AO, et al. Int J Pharm. 2008 Feb 12;349(1-2):108-16. doi: 10.1016/j.ijpharm.2007.07.042. Epub 2007 Aug 7. Int J Pharm. 2008. PMID: 17869459 - Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Zhang JA, et al. Eur J Pharm Biopharm. 2005 Jan;59(1):177-87. doi: 10.1016/j.ejpb.2004.06.009. Eur J Pharm Biopharm. 2005. PMID: 15567316 - Novel Taxol formulations: Taxol-containing liposomes.
Straubinger RM, Sharma A, Murray M, Mayhew E. Straubinger RM, et al. J Natl Cancer Inst Monogr. 1993;(15):69-78. J Natl Cancer Inst Monogr. 1993. PMID: 7912532 Review. - Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles.
Cho YW, Lee J, Lee SC, Huh KM, Park K. Cho YW, et al. J Control Release. 2004 Jun 18;97(2):249-57. doi: 10.1016/j.jconrel.2004.03.013. J Control Release. 2004. PMID: 15196752 - Paclitaxel and its formulations.
Singla AK, Garg A, Aggarwal D. Singla AK, et al. Int J Pharm. 2002 Mar 20;235(1-2):179-92. doi: 10.1016/s0378-5173(01)00986-3. Int J Pharm. 2002. PMID: 11879753 Review.
Cited by
- Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Shan L, Liu M, Wu C, Zhao L, Li S, Xu L, Cao W, Gao G, Gu Y. Shan L, et al. Int J Nanomedicine. 2015 Sep 1;10:5571-91. doi: 10.2147/IJN.S85402. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26366078 Free PMC article. - Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L. Cai L, et al. Int J Nanomedicine. 2012;7:4499-510. doi: 10.2147/IJN.S32817. Epub 2012 Aug 14. Int J Nanomedicine. 2012. PMID: 22923988 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources